# A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

Study · id `cardio:ct-nct07900633` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07900633](<https://clinicaltrials.gov/study/NCT07900633>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07900633

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

## Technical summary

Registry record NCT07900633. Randomized; double masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3000 participants (planned count; ClinicalTrials.gov record NCT07900633, source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)
- Planned start: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07900633, source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2029-11 (anticipated) (ClinicalTrials.gov record NCT07900633, source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07900633, source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Brazil; Canada; China; Czechia; France; Germany; Hungary; India; Italy; Japan; Mexico; Poland; Puerto Rico; Romania; South Korea; Spain; Türkiye; Ukraine (ClinicalTrials.gov record NCT07900633, source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07900633-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Acronym: ENLIGHTEN-10
- Condition: Obesity
- Condition: Overweight
- Condition: Cardiovascular Diseases
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Eloralintide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 9051759123aa390c501a311493f4698e779964c1364967ce0fc99b1e8531263b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
